This page shows what was measured, who it was measured in, and what that does not settle.
What Cobicistat does in the body
Systemic exposure of atazanavir or darunavir
From the FDA-approved label: Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A). Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · LW2E03M5PG · read 2026-08-29
Its recorded molecular formula is C40H53N7O5S2, weighing 776.0.
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-30
Where each sentence above came from
The recorded explanation is written in label language rather than for a beginner. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 49 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
clinical response
✗ The study did not show it
Who was studied
NCT04064632
How many people
1609
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
✗ The study did not show it
Who was studied
NCT01815736
How many people
1443
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percentage of Participants With Virologic Rebound (HIV-1 RNA >=50 Copies/mL) Cumulative Through Week 48
✗ The study did not show it
Who was studied
NCT02269917
How many people
1149
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48
✗ The study did not show it
Who was studied
NCT01797445
How many people
872
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
✗ The study did not show it
Who was studied
NCT01780506
How many people
872
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach
✗ The study did not show it
Who was studied
NCT02431247
How many people
725
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 14 kg.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The use of TYBOST with atazanavir and emtricitabine/tenofovir alafenamide (FTC/TAF) was studied in pediatric participants weighing at least 14 kg to less than 35 kg.”
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-30
On older people, the label states: “Clinical trials of TYBOST did not include sufficient numbers of participants aged 65 years and older to determine whether they respond differently from younger participants.”
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-30
On people who are pregnant, the label states: “TYBOST use during pregnancy has been evaluated in a limited number of individuals as reported by the APR, and available data show no significant difference in the rate of overall birth defects for cobicistat compared with the background rate for major defects of 2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) ( see Data ).”
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of cobicistat in human milk, the effects on the breastfed infant, or the effects on milk production.”
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-30
On people with reduced liver function, the label states: “No dosing adjustment of TYBOST is necessary for patients with mild-to-moderate hepatic impairment.”
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-30
On people with reduced kidney function, the label states: “No dosage adjustment of TYBOST is required in patients with renal impairment, including those with severe renal impairment.”
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
A different form was studied
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as tablet, for suspension, tablet, tablet, film coated, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
21 products list this as an active ingredient in the United States drug directory. 8 of them contain it and nothing else.
FDA National Drug Code directory · 61958-1401 · read 2026-08-29
They are sold as powder, tablet, tablet, film coated and tablet, for suspension, taken oral.
FDA National Drug Code directory · 61958-1401 · read 2026-08-29
The regulator's established pharmacologic class for it is breast cancer resistance protein inhibitors [moa], cytochrome p450 2d6 inhibitors [moa] and cytochrome p450 3a inhibitor [epc].
FDA National Drug Code directory · 61958-1401 · read 2026-08-29
7 published labels name it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-29
Tybost is oral at 3 DOSAGE FORMS AND STRENGTHS TYBOST, 150 mg: Orange, round, biconvex, film-coated tablets debossed with "GSI" on one side and plain faced on the other side of the tablet., recorded as fda label in effect 2026-02-10 in the United States.
US prescribing information · 3784c35c-e87f-410c-900b-8fd6313c6010 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (10)
Q1
On the Cobicistat label: indicated for what?
"TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 14 kg. ( 1.1 ) Limitations of Use : TYBOST is not…": indications and usage on Cobicistat's label. DailyMed label · 3784c35c-e87f-410c-900b-8fd6313c6010 · 2026-02-10
Q2
103 registered trials of Cobicistat — at which phases?
Registered studies posting no result
57 of 103
103 registered studies of Cobicistat: 36 phase1, 34 phase3, 18 phase4, 12 phase2, 5 na or unstated, 3 na, 1 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
safety (2), futility/efficacy (1), accrual/recruitment (4), sponsor decision unspecified (1) and other (2): Cobicistat's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"No participants enrolled"; 10 of 103 registered studies
Show the evidence
Trial
NCT02470650
withdrawn; "No participants enrolled"
NCT02503462
terminated; "No additional patients fulfilling the inclusion criteria"
NCT02697851
terminated; "Insufficient enrolment and "business reasons""
NCT03493568
terminated; "The futility analysis on 24-week results estimated that there was only 2% probability of verifying the study hypothesis of a higher proportion pat. with no residual viremia through 48w in arm E/C/F/TAF"
NCT03877536
withdrawn; "Feeder cohort study closed."
NCT04236453
terminated; "COVID-19 pandemic impacted the BE assessment of the trial. The clinical team decided to terminate the trial in order to start a new pivotal BE trial"
4 further recorded trials
NCT04240210
terminated; "Lack of eligible enrollees/ Halted by Primary Sponsor"
NCT04518228
terminated; "The study was closed to accrual early based on Study Monitoring Committee review indicating that the study objectives had either been achieved or could not be met within a reasonable timeframe for the then-open arms."
NCT05458102
terminated; "Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns."
NCT05494866
terminated; "lack of efficacy paired with high toxicity"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Cobicistat used Genvoya 150Mg-150Mg-200Mg-10Mg Tablet — over how long?
Human studies of Cobicistat used "Genvoya 150Mg-150Mg-200Mg-10Mg Tablet". ClinicalTrials.gov · 2026-09-01
3 recorded entries; human; tablet; also "Cobicistat 150 MG", "Tybost 150 mg tablet, GILEAD"
Show the evidence
human
NCT03493568
Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
NCT04322214
Cobicistat 150 MG
NCT06726382
tablet; Tybost 150 mg tablet, GILEAD
recorded 2026-09-01 · last checked 2026-09-04
Q5
Cobicistat's half-life is 3 to 4 hours — which schedules were studied?
3 to 4 hours; Elimination The terminal plasma half-life of cobicistat following administration of TYBOST is approximately 3 to 4 hours.
tmaxpharmacokinetics
3.5 hours; Absorption In a trial where participants were instructed to take coadministered TYBOST and darunavir with food, median cobicistat peak plasma concentrations were observed approximately 3.5 hours postdose.
metabolismpharmacokinetics
Metabolism Cobicistat is metabolized by CYP3A and to a minor extent by CYP2D6 enzymes and does not undergo glucuronidation.
recorded 2026-02-10 · last checked 2026-09-04
Q6
Which 36 trials of Cobicistat posted no result?
Posted no result
36 of 36 completed trials
Registrations
NCT01619527, NCT02203461, NCT02277600, NCT02325934, NCT02475135 and NCT02565888, and 30 more
Completion dates
oldest 2012-08; newest 2023-11-30
Show the evidence
Trial
NCT01619527
2012-08
NCT02203461
2014-10
NCT02277600
2015-01-12
NCT02325934
2015-02
NCT02475135
2015-08-14
NCT02565888
2016-01
14 further recorded trials
NCT02578550
2016-02
NCT02589158
2016-03
NCT02818348
2016-11-23
NCT02556268
2016-12-07
NCT01896622
2017-01-17
NCT02984852
2017-02
NCT02351908
2017-04
NCT03092206
2017-07-28
NCT02661373
2018-03-09
NCT03094507
2018-03-17
NCT02660905
2018-06
NCT02998320
2018-09-30
NCT03101644
2019-06-12
NCT02987530
2020-01-31
Q7
At the median, Cobicistat's trials enrolled 55 people — anything larger?
Median enrolment
55
Largest enrolment
1443
Registered trials counted
103
Q8
What do 799 spontaneous reports say about Cobicistat — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Cobicistat appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 799 reaction mentions were counted: drug interaction 198; weight increased 151; viral load increased 89; blood creatinine increased 83. FAERS via Open Targets · CHEMBL2095208 · 2026-06-24
Show the evidence
drug interaction
198
weight increased
151
viral load increased
89
blood creatinine increased
83
blood hiv rna increased
59
cushing's syndrome
52
4 more recorded rows
immune reconstitution inflammatory syndrome
48
drug resistance
46
cd4 lymphocytes decreased
37
virologic failure
36
recorded 2026-06-24 · last checked 2026-09-04
Q9
Which 10 reactions does Cobicistat's label not list?
TYBOST, in combination with atazanavir or darunavir, can alter the concentration of drugs metabolized by CYP3A or CYP2D6.
drug_interactions
Drugs that induce CYP3A can alter the concentrations of TYBOST, atazanavir and darunavir.
drug_interactions
( 4 , 5.3 , 7 , 12.3 ) 7.1 Potential Effect of Cobicistat (Coadministered with Atazanavir or Darunavir) on the Pharmacokinetics of Concomitant Drugs Cobicistat is an inhibitor of CYP3A and CYP2D6.
drug_interactions
The transporters that cobicistat inhibits include p-glycoprotein (P-gp), BCRP, OATP1B1, and OATP1B3.
drug_interactions
The plasma concentration of drugs that are primarily metabolized by CYP3A or CYP2D6, or are substrates of P-gp, BCRP, OATP1B1, or OATP1B3 may be increased if those drugs are coadministered with TYBOST.
drug_interactions
Based on in vitro data, cobicistat is not expected to induce CYP1A2 or CYP2B6 and based on in vivo data, cobicistat is not expected to induce MDR1 or, in general, CYP3A to a clinically significant extent.
2 more recorded rows
Interaction statementdrug_interactions
The induction effect of cobicistat on CYP2C9, CYP2C19, or UGT1A1 is unknown, but is expected to be low based on CYP3A in vitro induction data.
Interaction statementdrug_interactions
Coadministration of TYBOST with atazanavir or darunavir with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.
Cobicistat component of evotaz, Cobicistat component of genvoya, Cobicistat component of prezcobix, Cobicistat component of rezolsta, Cobicistat component of stribild, Cobicistat component of symtuza, Tybost, Genvoya, Stribild, Rezolsta, Evotaz, Symtuza
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.